292 related articles for article (PubMed ID: 24599717)
1. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
Zhang N; Wu ZM; McGowan E; Shi J; Hong ZB; Ding CW; Xia P; Di W
Cancer Sci; 2009 Dec; 100(12):2459-64. PubMed ID: 19769630
[TBL] [Abstract][Full Text] [Related]
3. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
4. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo.
Zhang X; Su Y; Zhang M; Sun Z
Cancer Lett; 2012 May; 318(1):93-8. PubMed ID: 22155346
[TBL] [Abstract][Full Text] [Related]
6. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
8. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.
Liu L; Chen C; Gong W; Li Y; Edin ML; Zeldin DC; Wang DW
J Pharmacol Exp Ther; 2011 Nov; 339(2):451-63. PubMed ID: 21846841
[TBL] [Abstract][Full Text] [Related]
9. ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.
Gu S; Chen C; Jiang X; Zhang Z
Chem Biol Interact; 2016 Feb; 245():100-9. PubMed ID: 26772155
[TBL] [Abstract][Full Text] [Related]
10. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
Okamura M; Hashimoto K; Shimada J; Sakagami H
Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
[TBL] [Abstract][Full Text] [Related]
12. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
13. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
[TBL] [Abstract][Full Text] [Related]
15. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
16. [Synergistic lethal effect of combined treatment of arsenic trioxide and aclacinomycin on human acute myeloid leukemia cell line KG-1a].
Ye YB; Xu XJ; Chen YH; Zhang MW; Qiu DF; Guo ZW; He HQ
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):256-262. PubMed ID: 28550664
[No Abstract] [Full Text] [Related]
17. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.
Bowling BD; Doudican N; Manga P; Orlow SJ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):37-43. PubMed ID: 18297286
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
20. The synergistic antitumor activity of arsenic trioxide and vitamin K2 in HL-60 cells involves increased ROS generation and regulation of the ROS-dependent MAPK signaling pathway.
Qu H; Tong D; Zhang Y; Kang K; Zhang Y; Chen L; Ren L
Pharmazie; 2013 Oct; 68(10):839-45. PubMed ID: 24273890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
